Werewolf Therapeutics, Inc. - Common Stock (HOWL)

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

(BPT) - Werewolf Therapeutics' clinical trials are underway and they're already changing lives.

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

HOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

HOWL stock results show that Werewolf Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

Delta Air Lines layoffs have the air travel company announcing minor adjustments to its corporate and management positions.

Carvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report.

Werewolf Therapeutics stock is taking off with heavy trading of HOWL shares after posting preliminary data from a clinical trial.

Werewolf Therapeutics Inc (NASDAQ: HOWL) released preliminary results from initial monotherapy dose-escalation cohorts of an ongoing Phase 1/1b trial of WTX-124 in patients with advanced or